A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema

A European Multi-Center, Multi-Country, Post-Authorisation, Observational Study (Registry) Of Patients With Hereditary Angioedema (HAE) Who Are Administered CINRYZE® (C1 Inhibitor [Human]) For The Treatment Or Prevention Of HAE Attacks

This observational (non-interventional) study is being conducted to characterize the safety and use of CINRYZE in routine clinical practice when administered for (1) routine prevention of angioedema attacks, (2) pre-procedure prevention of angioedema attacks, and/or (3) treatment of angioedema attacks.

Inclusion Criteria

All patients must:

• Have a diagnosis of HAE and be receiving CINRYZE for prevention or treatment of angioedema attacks
• Provide written informed consent/assent in compliance with applicable country-specific and local regulations

Exclusion Criteria

All patients must not:

• Be receiving CINRYZE in an investigational study
• Be receiving another HAE therapy as part of a clinical trial